Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Passes Below 200 Day Moving Average – Here’s What Happened

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.52 and traded as low as $0.37. Elite Pharmaceuticals shares last traded at $0.3704, with a volume of 1,179,674 shares trading hands.

Elite Pharmaceuticals Trading Down 2.4%

The stock has a 50 day simple moving average of $0.41 and a 200-day simple moving average of $0.52. The firm has a market cap of $398.96 million, a P/E ratio of 12.35 and a beta of 0.35. The company has a current ratio of 7.34, a quick ratio of 5.44 and a debt-to-equity ratio of 0.05.

Elite Pharmaceuticals (OTCMKTS:ELTP) last released its quarterly earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%. The company had revenue of $31.59 million for the quarter.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.